An audit comparing subcutaneous epoetin alfa to intravenous darbepoetin alfa in chronic hemodialysis patients

Dialysis and Transplantation

Volumn 34, Issue 6, 2005, Pages 358-367

  Summers, Shaun ^a   Winnett, Georgia ^a   Matijevic, Ante ^a   Carmichael, David ^a   Almond, Mike ^a  

^a SOUTHEND HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DOSE CALCULATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TREATMENT FAILURE;

EID: 20044367841     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Renal Association. Treatment of Adults and Children with Renal Failure: Standards and Audit Measure (3rd Ed.). London: Royal College of Physicians of London and Renal Association, 2002.
2. European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14(Suppl 5):1-50.
3. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1):S182-S238.
4. Besarab A. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 1993; 22(2 Suppl 1):13-22.
5. Mason NA, St. Peter WL, Bailie GR, Johnson CA. Clinical and practical perspectives on the use of intravenous vs. subcutaneous epoetin alfa in hemodialysis patients. Dial Transplant 2001; 30(8):522-529.
6. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47:331-335.
7. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346(7):469-475.
8. Weber G, Gross J, Kromminga A, Loew H, Eckardt K. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13:2381-2383.
9. Ortho Biotech, Division of Janssen Cilag. Important safety message. Eprex (epoetin alfa): reports of pure red cell aplasia (PRCA) [memorandum]. Raritan, NJ: Ortho Biotech, Division of Janssen Cilag, 2001.
10. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating factor (NESP). Nephrol Dial Transplant 2001; 16(Suppl 3):3-13.
11. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating factor compared with epoetin alpha in dialysis patients. J Am Soc Nephrol 1999; 10:2392-2395.
12. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ. European/Australian NESP 970200 Study Group. Randomised trial of darbepoetin alpha for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62(6):2167-2175.
13. Nissenson AR. Novel erythropoietin stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001; 38(6):1390-1397.
14. Horl W. IV darbepoetin alfa is more effective than i.v. rHuEPO in maintaining target Hb concentrations in patients with renal anemia. Nephrol Dial Transplant 2002; 17(Abstracts Suppl 1):24.
15. Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available preparations? [Editorial]. Nephrol Dial Transplant 2002; 17:2047-2051.
16. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 2003; 18(2):362-369.